Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.74 |
| ▸ | CES2 | O00748 | 2/20 | 0.74 |
| ▸ | CES1 | P23141 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | PARP1 | P09874 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.48 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17712861 | 0.94 | CES2 (0.71) | LMNACES2CES1KDM4EALDH1A1 | |
| Benzoin SCHEMBL418308 | 0.88 | CES2 (0.88) | LMNACES2CES1KDM4EALDH1A1 | |
| Benzoin SCHEMBL28211858 | 0.88 | CES2 (0.88) | LMNACES2CES1KDM4EALDH1A1 | |
| Benzoin SCHEMBL11590328 | 0.88 | CES2 (0.95) | LMNACES2CES1KDM4EALDH1A1 | |
| Benzoin SCHEMBL5833429 | 0.86 | CES2 (1.00) | LMNACES2CES1KDM4EALDH1A1 | |
| Benzoin SCHEMBL901258 | 0.86 | CES2 (1.00) | LMNACES2CES1KDM4EALDH1A1 | |
| Benzoin SCHEMBL2025536 | 0.86 | CES2 (1.00) | LMNACES2CES1KDM4EALDH1A1 | |
| Benzoin SCHEMBL145 | 0.86 | CES2 (1.00) | LMNACES2CES1KDM4EALDH1A1 | |
| Benzoin SCHEMBL10665271 | 0.86 | CES2 (1.00) | LMNACES2CES1KDM4EALDH1A1 | |
| Benzoin SCHEMBL28120851 | 0.86 | CES2 (1.00) | LMNACES2CES1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212637-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LTD (GB) | 2021-06-02 | — | — | EP | disclosed |
| EP-3362446-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | INDIVIOR UK LTD (GB) | 2020-12-02 | — | — | EP | disclosed |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| US-10577361-B2 | Dopamine D3 receptor antagonists having a morpholine moiety | INDIVIOR UK LIMITED (GB) | 2020-03-03 | — | — | US | disclosed |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2019-10-03 | — | — | US | disclosed |
| US-10239870-B2 | Dopamine D3 receptor antagonists | INDIVIOR UK LIMITED (GB) | 2019-03-26 | — | — | US | disclosed |
| US-20180297990-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | INDIVIOR INC. | 2018-10-18 | — | — | US | disclosed |
| US-20180282318-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS | INDIVIOR UK LIMITED (GB) | 2018-10-04 | — | — | US | disclosed |
| EP-3362446-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | Indivior UK Limited (GB) | 2018-08-22 | — | — | EP | disclosed |
| US-10000477-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-20170334895-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2017-11-23 | — | — | US | disclosed |
| EP-3212637-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | Indivior UK Limited (GB) | 2017-09-06 | — | — | EP | disclosed |
| WO-2017064488-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | INDIVIOR UK LIMITED (GB) | 2017-04-20 | — | — | WO | disclosed |
| WO-2016067043-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LIMITED (GB) | 2016-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282318-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS | DRD3, DRD2, DRD4 | LMNA 4734/4885CES2 892/4885CES1 3703/4885 |
| US-10577361-B2 | Dopamine D3 receptor antagonists having a morpholine moiety | DRD3, DRD2, SLC6A3 | LMNA 4648/4885CES2 736/4885CES1 3521/4885 |
| US-10000477-B2 | Dopamine D3 receptor antagonist compounds | DRD3, DRD2, DRD4 | LMNA 4686/4885CES2 993/4885CES1 3976/4885 |
| US-20180297990-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | DRD3, DRD2, SLC6A3 | LMNA 4648/4885CES2 736/4885CES1 3521/4885 |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | DRD3, DRD2, DRD4 | LMNA 4686/4885CES2 993/4885CES1 3976/4885 |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | DRD3, DRD2, DRD4 | LMNA 4686/4885CES2 993/4885CES1 3976/4885 |
| US-20170334895-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | DRD3, DRD2, DRD4 | LMNA 4686/4885CES2 993/4885CES1 3976/4885 |
| US-10239870-B2 | Dopamine D3 receptor antagonists | DRD3, DRD2, DRD4 | LMNA 4734/4885CES2 892/4885CES1 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.